Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Yes
100% of Medicare Part D and Medicare Advantage plans cover this drug.It depends. Which coverage stage are you in? Click on a tab below…
$42 – $417
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your myrbetriq prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Myrbetriq (mirabegron) relaxes the muscles of the urinary bladder, reducing bladder spasms.
Myrbetriq is used to treat the symptoms of overactive bladder, such as frequent or urgent urination and urinary incontinence.
Myrbetriq is often used in combination with another overactive bladder medicine, solifenacin.
Myrbetriq may also be used for purposes not listed in this medication guide.
You should not use Myrbetriq if you have
A condition called angioedema can occur after taking Myrbetriq. Angioedema is a condition that leads to face, lip, tongue, throat swelling, difficulty breathing and can be fatal. Seek emergency attention immediately if these symptoms occur.
It may take up to 8 weeks before your symptoms improve. Keep using this medicine as directed and tell your doctor if your symptoms do not improve after 8 weeks of treatment.
You should not use Myrbetriq if you are allergic to mirabegron, or if you have:
end stage renal disease (kidney failure);
severe liver disease; or
severe uncontrolled high blood pressure.
To make sure this medicine is safe for you, tell your doctor if you have:
kidney disease;
liver disease;
high blood pressure; or
trouble emptying your bladder (very little urine or a weak stream of urine).
It is not known whether Myrbetriq will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It is not known whether Myrbetriq passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.
Myrbetriq is not approved for use by anyone younger than 18 years old.
Myrbetriq is usually taken once per day. Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.
You may take Myrbetriq with or without food.
Take this medicine with a full glass of water.
Do not crush, chew, or break Myrbetriq. Swallow it whole.
Your blood pressure will need to be checked often while taking Myrbetriq.
It may take up to 8 weeks before your symptoms improve. Keep using the medication as directed and tell your doctor if your symptoms do not improve.
Store at room temperature away from moisture and heat.
Usual Adult Dose for Urinary Incontinence and Urinary Frequency:
Initial dose: 25 mg orally once daily
Maintenance dose: 25 to 50 mg orally once daily based on individual patient efficacy and tolerability.
Skip the missed dose and wait until your next scheduled dose. Do not take extra medicine to make up the missed dose.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Get emergency medical help if you have any of these signs of an allergic reaction to Myrbetriq: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using this medicine and call your doctor at once if you have:
fast or pounding heartbeat;
pain or burning when you urinate;
painful or difficult urination; or
severe headache, blurred vision, pounding in your neck or ears, nosebleed, anxiety, confusion, severe chest pain, shortness of breath, irregular heartbeats.
Common Myrbetriq side effects may include:
increased blood pressure;
headache, dizziness;
cold symptoms such as stuffy nose, sneezing, sore throat; or
constipation, diarrhea.
dry mouth; or.
back pain, joint pain.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all your current medicines and any you start or stop using during your treatment with Myrbetriq, especially:
digoxin;
flecainide;
warfarin (Coumadin, Jantoven);
propafenone; or
thioridazine.
metoprolol; or
desipramine.
This list is not complete. Other drugs may interact with Myrbetriq, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medicine only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Myrbetriq (www.drugs.com/myrbetriq.html).
Note: This document contains side effect information about mirabegron. Some of the dosage forms listed on this page may not apply to the brand name Myrbetriq.
Common side effects of Myrbetriq include: hypertension. Other side effects include: urinary tract infection. See below for a comprehensive list of adverse effects.
Applies to mirabegron: oral tablet extended release
Along with its needed effects, mirabegron (the active ingredient contained in Myrbetriq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking mirabegron:
More common
Rare
Incidence not known
Some side effects of mirabegron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Rare
Applies to mirabegron: oral tablet extended release
The more commonly reported adverse reactions have included hypertension, nasopharyngitis, urinary tract infection, and headache.
Very common (10% or more): Hypertension (up to 11.3%)
Common (1% to 10%): Tachycardia
Uncommon (0.1% to 1%): Atrial fibrillation, palpitations, worsening of preexisting hypertension
In 2 randomized controlled studies, dose-related increases in supine blood pressure occurred. At the maximum recommended dose of 50 mg per day, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg.
Uncommon (0.1% to 1%): Urticaria, rash, pruritus, lip edema, macular rash, papular rash
Rare (less than 0.1%): Leukocytoclastic vasculitis, purpura, angioedema
Angioedema of the face, lips, tongue, and/or larynx has been reported. In some case, this occurred after the first dose or after multiple doses.
Common (1% to 10%): Nausea, constipation, diarrhea, abdominal pain
Uncommon (0.1% to 1%): Dyspepsia, gastritis, abdominal distension
Rare (less than 0.1%): Lip edema
Common (1% to 10%): Urinary tract infection
Uncommon (0.1% to 1%): Nephrolithiasis, bladder pain, cystitis, vaginal infection, vulvovaginal pruritus
Postmarketing reports: Urinary retention
Urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonists for the treatment of overactive bladder. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patient taking this drug.
Common (1% to 10%): Arthralgia
Uncommon (0.1% to 1%): Joint swelling
Common (1% to 10%): Headache, fatigue, dizziness
Uncommon (0.1% to 1%): Glaucoma, blurred vision, dry eyes
Rare (less than 0.1%): Eyelid edema
Rare (less than 0.1%): Prostate cancer
Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis
Uncommon (0.1% to 1%): Increased ALT, AST, and GGT
The majority of patients reporting confusion, hallucinations, insomnia, and anxiety had preexisting conditions or were using concomitant medications that may have contributed to these events.
Postmarketing reports: Confusion, hallucinations, insomnia, anxiety
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Myrbetriq (www.drugs.com/myrbetriq.html).
March 27, 2020
March 27, 2020
March 28, 2020
March 27, 2020
March 24, 2020
March 26, 2020
